MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Walter Reinisch  ¹     Severine Vermeire  ²     Charlotte Hedin  ³     David T. Rubin  ⁴     Julian Panés  ⁵     Huiwen Deng  ⁶     Si Xuan  ⁶     Lani Wegrzyn  ⁶     John Liu  ⁶     Dapo Ilo  ⁶     Wen Zhou  ⁶     Yuri Sanchez Gonzalez  ⁶     Remo Panaccione  ^7    
1 Medical University of Vienna, Wien, Austria
² University Hospital Leuven, Leuven, Belgium
³ Karolinska Institutet, Stockholm, Sweden
⁴ University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States
⁵ Hospital Clinic Barcelona, Barcelona, Spain
⁶ AbbVie Inc., North Chicago, United States
⁷ University of Calgary, Calgary, Canada

Session
Clinical trials in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)